Selenoproteins and cardiovascular stress

Thrombosis and Haemostasis

Volumn 113, Issue 3, 2015, Pages 494-504

  Rose, Aaron H ^a   Hoffmann, Peter R ^a  

^a UNIVERSITY OF HAWAII   (United States)

Author keywords

Cardiovascular; Heart; Oxidative stress; Selenium; Selenoproteins

Indexed keywords

CD36 ANTIGEN; DEIODINASE; DOXIRUBICIN; FLAVINE ADENINE NUCLEOTIDE; GLUTATHIONE PEROXIDASE; METHIONINE SULFOXIDE REDUCTASE; METHIONINE SULFOXIDE REDUCTASE A; METHIONINE SULFOXIDE REDUCTASE B; NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; OXIDOREDUCTASE; SELENIUM; SELENOPHOSPHATE SYNTHETASE; SELENOPROTEIN; SELENOPROTEIN 15; SELENOPROTEIN H; SELENOPROTEIN I; SELENOPROTEIN K; SELENOPROTEIN M; SELENOPROTEIN N; SELENOPROTEIN O; SELENOPROTEIN P; SELENOPROTEIN S; SELENOPROTEIN T; SELENOPROTEIN V; SELENOPROTEIN W; THIOREDOXIN REDUCTASE; THYROID HORMONE; UNCLASSIFIED DRUG; ANTIOXIDANT;

APOPTOSIS; ARTICLE; CARDIOVASCULAR DISEASE; CELL SURVIVAL; DNA POLYMORPHISM; ENDOPLASMIC RETICULUM STRESS; HEART FUNCTION; HEART MUSCLE CONTRACTILITY; HEART OUTPUT; HEART PROTECTION; HEART RATE; HEART VENTRICLE HYPERTROPHY; HOMOCYSTEINE DYSREGULATION; HUMAN; ISCHAEMIA REPERFUSION; KESHAN DISEASE; MACROPHAGE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SYNTHESIS; REGULATORY MECHANISM; THYROID HORMONE METABOLISM; TOXICITY; ANIMAL; CARDIOVASCULAR SYSTEM; DIET; METABOLISM; OXIDATION REDUCTION REACTION; PATHOPHYSIOLOGY; PHYSIOLOGICAL STRESS;

ANIMALS; ANTIOXIDANTS; CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; DIET; GLUTATHIONE PEROXIDASE; HUMANS; METHIONINE SULFOXIDE REDUCTASES; OXIDATION-REDUCTION; OXIDATIVE STRESS; SELENIUM; SELENOPROTEINS; STRESS, PHYSIOLOGICAL; THIOREDOXIN-DISULFIDE REDUCTASE;

EID: 84924189630     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH14-07-0603     Document Type: Article

References (150)

1. Fairweather-Tait SJ, et al. Selenium in human health and disease. Antioxid Redox Signal 2011; 14: 1337–1383.
2. Rayman MP. Selenium and human health. Lancet 2012; 379: 1256–1268.
3. U. S. Department of Agriculture ARS. USDA National Nutrient Database for Standard Reference, Release 16. Nutrient Data Laboratory Home Page. Available at: http://www.nal.usda.gov/fnic/foodcomp.
4. Longnecker MP, et al. Selenium in diet, blood, and toenails in relation to human health in a seleniferous area. Am J Clin Nutr 1991; 53: 1288–1294.
5. Metes-Kosik N, et al. Both selenium deficiency and modest selenium supplementation lead to myocardial fibrosis in mice via effects on redox-methylation balance. Mol Nutr Food Res 2012; 56: 1812–1824.
6. Stranges S, et al. Selenium status and cardiometabolic health: state of the evidence. Nutrition, metabolism, and cardiovascular diseases: NMCD 2010; 20: 754–760.
7. Joseph J. Selenium and cardiometabolic health: inconclusive yet intriguing evidence. Am J Med Sci 2013; 346: 216–220.
8. Rees K, et al. Selenium supplementation for the primary prevention of cardiovascular disease. Cochrane Datab Syst Rev 2013; 1: CD009671.
9. Hoffmann PR, Berry MJ. Selenoprotein synthesis: a unique translational mechanism used by a diverse family of proteins. Thyroid 2005; 15: 769–775.
10. Seeher S, et al. Post-transcriptional control of selenoprotein biosynthesis. Curr Prot Pept Sci 2012; 13: 337–346.
11. Squires JE, Berry MJ. Eukaryotic selenoprotein synthesis: mechanistic insight incorporating new factors and new functions for old factors. IUBMB Life 2008; 60: 232–235.
12. Schmidt RL, Simonovic M. Synthesis and decoding of selenocysteine and human health. Croat Med J 2012; 53: 535–550.
13. Kryukov GV, et al. Characterisation of mammalian selenoproteomes. Science 2003; 300: 1439–1443.
14. Reeves MA, Hoffmann PR. The human selenoproteome: recent insights into functions and regulation. Cell Mol Life Sci 2009; 66: 2457–2478.
15. Rotruck JT, et al. Selenium: biochemical role as a component of glutathione peroxidase. Science 1973; 179: 588–590.
16. Flohe L, et al. Glutathione peroxidase: a selenoenzyme. FEBS Lett 1973; 32: 132–134.
17. Kim HY, Gladyshev VN. Methionine sulfoxide reduction in mammals: characterisation of methionine-R-sulfoxide reductases. Mol Biol Cell 2004; 15: 1055–1064.
18. Harman D. Aging: a theory based on free radical and radiation chemistry. J Gerontol 1956; 11: 298–300.
19. Petropoulos I, Friguet B. Maintenance of proteins and aging: the role of oxidized protein repair. Free Rad Res 2006; 40: 1269–1276.
20. Kasaikina MV, et al. Reduced utilisation of selenium by naked mole rats due to a specific defect in GPx1 expression. J Biol Chem 2011; 286: 17005–1714.
21. Ran Q, et al. Reduction in glutathione peroxidase 4 increases life span through increased sensitivity to apoptosis. J Gerontol Series A Biol Sci Med Sci 2007; 62: 932–942.
22. Muller FL, et al. Trends in oxidative aging theories. Free Radic Biol Med 2007; 43: 477–503.
23. Dikiy A, et al. SelT, SelW, SelH, and Rdx12: genomics and molecular insights into the functions of selenoproteins of a novel thioredoxin-like family. Biochemistry 2007; 46: 6871–6882.
24. Panee J, et al. Selenoprotein H is a redox-sensing high mobility group family DNA-binding protein that up-regulates genes involved in glutathione synthesis and phase II detoxification. J Biol Chem 2007; 282: 23759–23765.
25. Novoselov SV, et al. Selenoprotein H is a nucleolar thioredoxin-like protein with a unique expression pattern. J Biol Chem 2007; 282: 11960–11968.
26. Grumolato L, et al. Selenoprotein T is a PACAP-regulated gene involved in intracellular Ca2+ mobilisation and neuroendocrine secretion. FASEB J 2008; 22: 1756-1768.
27. Prevost G, et al. The PACAP-regulated gene selenoprotein T is abundantly expressed in mouse and human beta-cells and its targeted inactivation impairs glucose tolerance. Endocrinology 2013; 154: 3796–3806.
28. Korotkov KV, et al. Association between the 15-kDa selenoprotein and UDPglucose: glycoprotein glucosyltransferase in the endoplasmic reticulum of mammalian cells. J Biol Chem 2001; 276: 15330–15336.
29. Ferguson AD, et al. NMR structures of the selenoproteins Sep15 and SelM reveal redox activity of a new thioredoxin-like family. J Biol Chem 2006; 281: 3536–3543.
30. Lu C, et al. Identification and characterisation of selenoprotein K: an antioxidant in cardiomyocytes. FEBS Lett 2006; 580: 5189–5197.
31. Shchedrina VA, et al. Selenoprotein K binds multiprotein complexes and is involved in the regulation of endoplasmic reticulum homeostasis. J Biol Chem 2011; 286: 42937–42948.
32. Verma S, et al. Selenoprotein K knockout mice exhibit deficient calcium flux in immune cells and impaired immune responses. J Immunol 2011; 186: 2127–2137.
33. Huang Z, et al. Stimulation of unprimed macrophages with immune complexes triggers a low output of nitric oxide by calcium-dependent neuronal nitric-oxide synthase. J Biol Chem 2012; 287: 4492–4502.
34. Meiler S, et al. Selenoprotein K is required for palmitoylation of CD36 in macrophages: implications in foam cell formation and atherogenesis. J Leukocyte Biol 2013; 93: 771–780.
35. Bosl MR, et al. Early embryonic lethality caused by targeted disruption of the mouse selenocysteine tRNA gene (Trsp). Proc Natl Acad Sci USA 1997; 94: 5531–5534.
36. Conrad M. Transgenic mouse models for the vital selenoenzymes cytosolic thioredoxin reductase, mitochondrial thioredoxin reductase and glutathione peroxidase 4. Biochim Biophys Acta 2009; 1790: 1575–1585.
37. Yant LJ, et al. The selenoprotein GPX4 is essential for mouse development and protects from radiation and oxidative damage insults. Free Radic Biol Med 2003; 34: 496–502.
38. Jakupoglu C, et al. Cytoplasmic thioredoxin reductase is essential for embryogenesis but dispensable for cardiac development. Mol Cell Biol 2005; 25: 1980–1988.
39. Conrad M, et al. Essential role for mitochondrial thioredoxin reductase in hematopoiesis, heart development, and heart function. Mol Cell Biol 2004; 24: 9414–9423.
40. Prasad R, et al. Thioredoxin Reductase 2 (TXNRD2) Mutation Associated With Familial Glucocorticoid Deficiency (FGD). J Clin Endocrinol Metabol 2014; 99: E1556–1563.
41. Cheng WH, et al. Cellular glutathione peroxidase knockout mice express normal levels of selenium-dependent plasma and phospholipid hydroperoxide glutathione peroxidases in various tissues. J Nutr 1997; 127: 1445–1450.
42. Esworthy RS, et al. Mice with combined disruption of Gpx1 and Gpx2 genes have colitis. Am J Physiol Gastrointest Liver Physiol 2001; 281: G848–855.
43. Schneider MJ, et al. Targeted disruption of the type 1 selenodeiodinase gene (Dio1) results in marked changes in thyroid hormone economy in mice. Endocrinology 2006; 147: 580–589.
44. Schneider MJ, et al. Targeted disruption of the type 2 selenodeiodinase gene (DIO2) results in a phenotype of pituitary resistance to T4. Mol Endocrinol 2001; 15: 2137–2148.
45. Hill KE, et al. Deletion of selenoprotein P alters distribution of selenium in the mouse. J Biol Chem 2003; 278: 13640–13646.
46. Schomburg L, et al. Gene disruption discloses role of selenoprotein P in selenium delivery to target tissues. Biochem J 2003; 370: 397–402.
47. Fomenko DE, et al. MsrB1 (methionine-R-sulfoxide reductase 1) knock-out mice: roles of MsrB1 in redox regulation and identification of a novel selenoprotein form. J Biol Chem 2009; 284: 5986–5993.
48. Pitts MW, et al. Deletion of selenoprotein M leads to obesity without cognitive deficits. J Biol Chem 2013; 288: 26121–26134.
49. Rederstorff M, et al. Increased muscle stress-sensitivity induced by selenoprotein N inactivation in mouse: a mammalian model for SEPN1-related myopathy. PloS one 2011; 6: e23094.
50. Kasaikina MV, et al. Roles of the 15-kDa selenoprotein (Sep15) in redox homeostasis and cataract development revealed by the analysis of Sep 15 knockout mice. J Biol Chem 2011; 286: 33203–33212.
51. Hoffmann PR, et al. The selenoproteome exhibits widely varying, tissue-specific dependence on selenoprotein P for selenium supply. Nucleic Acids Res 2007; 35: 3963–3973.
52. Kelly VP, et al. The distal sequence element of the selenocysteine tRNA gene is a tissue-dependent enhancer essential for mouse embryogenesis. Mol Cell Biol 2005; 25: 3658–3669.
53. Hernandez A, St Germain DL. Thyroid hormone deiodinases: physiology and clinical disorders. Curr Opin Pediatr 2003; 15: 416–420.
54. Combs GF, Jr., et al. Determinants of selenium status in healthy adults. Nutrition J 2011; 10: 75.
55. Tanguy S, et al. Impact of dietary selenium intake on cardiac health: experimental approaches and human studies. Mol Nutr Food Res 2012; 56: 1106–1121.
56. Joseph J, Loscalzo J. Selenistasis: epistatic effects of selenium on cardiovascular phenotype. Nutrients 2013; 5: 340–358.
57. Brigelius-Flohe R, Maiorino M. Glutathione peroxidases. Biochim Biophys Acta 2013; 1830: 3289–3303.
58. Forgione MA, et al. Heterozygous cellular glutathione peroxidase deficiency in the mouse: abnormalities in vascular and cardiac function and structure. Circulation 2002; 106: 1154–1158.
59. Das DK, et al. Preconditioning potentiates molecular signalling for myocardial adaptation to ischaemia. Ann NY Acad Sci 1996; 793: 191–209.
60. Yoshida T, et al. Transgenic mice overexpressing glutathione peroxidase are resistant to myocardial ischaemia reperfusion injury. J Mol Cell Cardiol 1996; 28: 1759–1767.
61. Yoshida T, et al. Glutathione peroxidase knockout mice are susceptible to myocardial ischaemia reperfusion injury. Circulation 1997; 96 (9 Suppl): II-216–20.
62. Maulik N, et al. Regulation of cardiomyocyte apoptosis in ischaemic reperfused mouse heart by glutathione peroxidase. Mol Cell Biochem 1999; 196: 13–21.
63. Venardos K, et al. Effects of dietary selenium on glutathione peroxidase and thioredoxin reductase activity and recovery from cardiac ischaemia-reperfusion. J Trace Elem Med Biol 2004; 18: 81–88.
64. Venardos K, et al. Effects of dietary selenium on post-ischaemic expression of antioxidant mRNA. Mol Cell Biochem 2005; 270: 131–138.
65. Seshadri N, Robinson K. Homocysteine and coronary risk. Curr Cardiol Rep 1999; 1: 91–98.
66. Upchurch GR, Jr., et al. Homocyst(e)ine decreases bioavailable nitric oxide by a mechanism involving glutathione peroxidase. J Biol Chem 1997; 272: 17012–17017.
67. Zhang X, et al. Effects of homocysteine on endothelial nitric oxide production. Am J Physiol Renal Physiol 2000; 279: F671–678.
68. Starkebaum G, Harlan JM. Endothelial cell injury due to copper-catalysed hydrogen peroxide generation from homocysteine. J Clin Invest 1986; 77: 1370–1376.
69. Dayal S, et al. Deficiency of glutathione peroxidase-1 sensitizes hyperhomocysteinemic mice to endothelial dysfunction. Arterioscler Thromb Vasc Biol 2002; 22: 1996–2002.
70. Weiss N, et al. Overexpression of cellular glutathione peroxidase rescues homocyst(e)ine-induced endothelial dysfunction. Proc Natl Acad Sci USA 2001; 98: 12503–12508.
71. Weiss Sachdev S, Sunde RA. Selenium regulation of transcript abundance and translational efficiency of glutathione peroxidase-1 and –4 in rat liver. Biochem J 2001; 357: 851–858.
72. Thomson CD. Assessment of requirements for selenium and adequacy of selenium status: a review. Eur J Clin Nutr 2004; 58: 391–402.
73. Handy DE, et al. Homocysteine down-regulates cellular glutathione peroxidase (GPx1) by decreasing translation. J Biol Chem 2005; 280: 15518–15525.
74. Danesi F, et al. Counteraction of adriamycin-induced oxidative damage in rat heart by selenium dietary supplementation. J Agric Food Chem 2006; 54: 1203–1208.
75. Quiles JL, et al. Antioxidant nutrients and adriamycin toxicity. Toxicology 2002; 180: 79–95.
76. Xiong Y, et al. Attenuation of doxorubicin-induced contractile and mitochondrial dysfunction in mouse heart by cellular glutathione peroxidase. Free Radic Biol Med 2006; 41: 46–55.
77. Gao J, et al. Glutathione peroxidase 1-deficient mice are more susceptible to doxorubicin-induced cardiotoxicity. Biochim Biophys Acta 2008; 1783: 2020–2029.
78. Zhou S, et al. The Role of Nrf2-Mediated Pathway in Cardiac Remodelling and Heart Failure. Oxidat Med Cell Longevity 2014; 2014: 260429.
79. Kimura W, Muralidhar S, Canseco DC, et al. Redox signalling in cardiac renewal. Antioxid Redox Signal 2014; 21: 1660-1673.
80. Reinke EN, et al. Translational regulation of GPx-1 and GPx-4 by the mTOR pathway. PloS one 2014; 9: e93472.
81. Ramprasath T, Selvam GS. Potential impact of genetic variants in Nrf2 regulated antioxidant genes and risk prediction of diabetes and associated cardiac complications. Curr Med Chem 2013; 20: 4680–4693.
82. Dreger H, et al. Nrf2-dependent upregulation of antioxidative enzymes: a novel pathway for proteasome inhibitor-mediated cardioprotection. Cardiovasc Res 2009; 83: 354–361.
83. Hashmi S, Al-Salam S. Hypoxia-inducible factor-1 alpha in the heart: a double agent? Cardiol Rev 2012; 20: 268–273.
84. Philip B, et al. HIF expression and the role of hypoxic microenvironments within primary tumours as protective sites driving cancer stem cell renewal and metastatic progression. Carcinogenesis 2013; 34: 1699–1707.
85. Kimura W, Sadek HA. The cardiac hypoxic niche: emerging role of hypoxic microenvironment in cardiac progenitors. Cardiovasc Diagn Ther 2012; 2: 278–289.
86. Sena LA, Chandel NS. Physiological roles of mitochondrial reactive oxygen species. Mol Cell 2012; 48: 158–167.
87. Bell EL, et al. The Qo site of the mitochondrial complex III is required for the transduction of hypoxic signalling via reactive oxygen species production. J Cell Biol 2007; 177: 1029–1036.
88. Moos PJ, et al. Electrophilic prostaglandins and lipid aldehydes repress redoxsensitive transcription factors p53 and hypoxia-inducible factor by impairing the selenoprotein thioredoxin reductase. J Biol Chem 2003; 278: 745–750.
89. Wheaton WW, Chandel NS. Hypoxia. 2. Hypoxia regulates cellular metabolism. Am J Physiol Cell Physiol 2011; 300: C385–393.
90. Scortegagna M, et al. Multiple organ pathology, metabolic abnormalities and impaired homeostasis of reactive oxygen species in Epas1-/- mice. Nature Gen 2003; 35: 331–340.
91. Sciarretta S, et al. Mammalian target of rapamycin signalling in cardiac physiology and disease. Circ Res 2014; 114: 549–564.
92. Ayaz M, Turan B. Selenium prevents diabetes-induced alterations in [Zn2+]i and metallothionein level of rat heart via restoration of cell redox cycle. Am J Physiol Heart Circ Physiol 2006; 290: H1071–1080.
93. McClung JP, et al. Development of insulin resistance and obesity in mice overexpressing cellular glutathione peroxidase. Proc Natl Acad Sci USA 2004; 101: 8852–8857.
94. Fujita A, et al. Increased gene expression of antioxidant enzymes in KKAy diabetic mice but not in STZ diabetic mice. Diabetes Res Clin Pract 2005; 69: 113–119.
95. Iwata K, et al. The activity of aldose reductase is elevated in diabetic mouse heart. J Pharmacol Sci 2007; 103: 408–416.
96. Li GS, et al. Keshan disease: an endemic cardiomyopathy in China. Hum Pathol 1985; 16: 602–609.
97. Xu GL, et al. Further investigation on the role of selenium deficiency in the aetiology and pathogenesis of Keshan disease. Biomed Environ Sci 1997; 10: 316–326.
98. Su C, et al. Preliminary resluts of viral etiology of Keshan disease. Chin Med J 1979; 59: 466–472.
99. Li Y, et al. Detection of enteroviral RNA in parafin-embedded myocardial tissue from patients with Kehan disease by nested PCR. Chung Hua I Hsueh Tsa Chih 1995; 75: 344–345.
100. Peng T, et al. Characterisation of enterovirus isolates from patients with heart muscle disease in a selenium-deficient area of China. J Clin Microbiol 2000; 38: 3538–3543.
101. Beck MA, et al. Benign human enterovirus becomes virulent in selenium-deficient mice. J Med Virol 1994; 43: 166–170.
102. Beck MA, et al. Glutathione peroxidase protects mice from viral-induced myocarditis. Faseb J 1998; 12: 1143–1149.
103. Pei J, et al. Oxidative stress is involved in the pathogenesis of Keshan disease (an endemic dilated cardiomyopathy) in China. Oxidat Med Cell Longev 2013; 2013: 474203.
104. Freedman JE, et al. Glutathione peroxidase potentiates the inhibition of platelet function by S-nitrosothiols. J Clin Invest 1995; 96: 394–400.
105. Freedman JE, et al. Decreased platelet inhibition by nitric oxide in two brothers with a history of arterial thrombosis. J Clin Invest 1996; 97: 979–987.
106. Kenet G, et al. Plasma glutathione peroxidase deficiency and platelet insensitivity to nitric oxide in children with familial stroke. Arterioscler Thromb Vasc Biol 1999; 19: 2017–2023.
107. Bierl C, et al. Determinants of human plasma glutathione peroxidase (GPx-3) expression. J Biol Chem 2004; 279: 26839–26845.
108. Voetsch B, et al. Promoter polymorphisms in the plasma glutathione peroxidase (GPx-3) gene: a novel risk factor for arterial ischaemic stroke among young adults and children. Stroke 2007; 38: 41–49.
109. Voetsch B, et al. Role of promoter polymorphisms in the plasma glutathione peroxidase (GPx-3) gene as a risk factor for cerebral venous thrombosis. Stroke 2008; 39: 303–307.
110. Grond-Ginsbach C, Lichy C, Padovani A, et al. GPx-3 gene promoter variation and the risk of arterial ischaemic stroke. Stroke 2007; 38: e23; author reply e24.
111. Iwata K, et al. Increased gene expression of glutathione peroxidase-3 in diabetic mouse heart. Biol Pharm Bull 2006; 29: 1042–1045.
112. Brigelius-Flohe R, et al. Selenium-dependent enzymes in endothelial cell function. Antioxid Redox Signal 2003; 5: 205–215.
113. Hoffmann FW, et al. Specific antioxidant selenoproteins are induced in the heart during hypertrophy. Arch Biochem Biophys 2011; 512: 38–44.
114. Hollander JM, et al. Overexpression of PHGPx and HSP60/10 protects against ischaemia/reoxygenation injury. Free Radic Biol Med 2003; 35: 742–751.
115. Banning A, et al. Inhibition of basal and interleukin-1-induced VCAM-1 expression by phospholipid hydroperoxide glutathione peroxidase and 15-lipoxygenase in rabbit aortic smooth muscle cells. Free Radic Biol Med 2004; 36: 135–144.
116. Pepper MP, et al. Impacts of dietary selenium deficiency on metabolic phenotypes of diet-restricted GPX1-overexpressing mice. Antioxid Redox Signal 2011; 14: 383–390.
117. Arner ES, Holmgren A. Physiological functions of thioredoxin and thioredoxin reductase. Eur J Biochem 2000; 267: 6102–6109.
118. Maulik N, Das DK. Emerging potential of thioredoxin and thioredoxin interacting proteins in various disease conditions. Biochim Biophys Acta 2008; 1780: 1368-1382.
119. Gilbert HF. Molecular and cellular aspects of thiol-disulfide exchange. Adv Enzymol Rel Areas Mol Biol 1990; 63: 69–172.
120. Gasdaska PY, et al. Cloning and sequencing of a human thioredoxin reductase. FEBS Lett 1995; 373: 5–9.
121. Gasdaska PY, et al. Cloning, sequencing and functional expression of a novel human thioredoxin reductase. FEBS Lett 1999; 442: 105–111.
122. Sun QA, et al. Selenoprotein oxidoreductase with specificity for thioredoxin and glutathione systems. Proc Natl Acad Sci USA 2001; 98: 3673–3678.
123. Berndt C, et al. Thiol-based mechanisms of the thioredoxin and glutaredoxin systems: implications for diseases in the cardiovascular system. Am J Physiol Heart Circ Physiol 2007; 292: H1227–1236.
124. World CJ, et al. Thioredoxin in the cardiovascular system. J Mol Med 2006; 84: 997–1003.
125. Ago T, Sadoshima J. Thioredoxin and ventricular remodelling. J Mol Cell Cardiol 2006; 41: 762–773.
126. Yamamoto M, et al. Inhibition of endogenous thioredoxin in the heart increases oxidative stress and cardiac hypertrophy. J Clin Invest 2003; 112: 1395–1406.
127. Andersson M, et al. NK-lysin, a disulfide-containing effector peptide of T-lymphocytes, is reduced and inactivated by human thioredoxin reductase. Implication for a protective mechanism against NK-lysin cytotoxicity. J Biol Chem 1996; 271: 10116–10120.
128. Nordberg J, Arner ES. Reactive oxygen species, antioxidants, and the mammalian thioredoxin system. Free Radic Biol Med 2001; 31: 1287–1312.
129. Xia L, et al. The mammalian cytosolic selenoenzyme thioredoxin reductase reduces ubiquinone. A novel mechanism for defense against oxidative stress. J Biol Chem 2003; 278: 2141–2146.
130. Pimentel DR, et al. Strain-stimulated hypertrophy in cardiac myocytes is mediated by reactive oxygen species-dependent Ras S-glutathiolation. J Mol Cell Cardiol 2006; 41: 613–622.
131. Amin JK, et al. Reactive oxygen species mediate alpha-adrenergic receptorstimulated hypertrophy in adult rat ventricular myocytes. J Mol Cell Cardiol 2001; 33: 131–139.
132. Tanaka K, et al. Redox regulation of MAPK pathways and cardiac hypertrophy in adult rat cardiac myocyte. J Am Coll Cardiol 2001; 37: 676–685.
133. Nakamura K, et al. Inhibitory effects of antioxidants on neonatal rat cardiac myocyte hypertrophy induced by tumor necrosis factor-alpha and angiotensin II. Circulation 1998; 98: 794–799.
134. Remondino A, et al. Beta-adrenergic receptor-stimulated apoptosis in cardiac myocytes is mediated by reactive oxygen species/c-Jun NH2-terminal kinasedependent activation of the mitochondrial pathway. Circ Res 2003; 92: 136–138.
135. Wang L, Proud CG. Ras/Erk signalling is essential for activation of protein synthesis by Gq protein-coupled receptor agonists in adult cardiomyocytes. Circ Res 2002; 91: 821–829.
136. Kuster GM, et al. Alpha-adrenergic receptor-stimulated hypertrophy in adult rat ventricular myocytes is mediated via thioredoxin-1-sensitive oxidative modification of thiols on Ras. Circulation 2005; 111: 1192–1198.
137. Kryukov GV, et al. Selenoprotein R is a zinc-containing stereo-specific methionine sulfoxide reductase. Proc Natl Acad Sci USA 2002; 99: 4245–4250.
138. Picot CR, et al. Alterations in mitochondrial and cytosolic methionine sulfoxide reductase activity during cardiac ischaemia and reperfusion. Exp Gerontol 2006; 41: 663–667.
139. Lee BC, et al. MsrB1 and MICALs regulate actin assembly and macrophage function via reversible stereoselective methionine oxidation. Mol Cell 2013; 51: 397–404.
140. Erickson JR, et al. A dynamic pathway for calcium-independent activation of CaMKII by methionine oxidation. Cell 2008; 133: 462–474.
141. Purohit A, et al. Oxidized Ca(2+)/calmodulin-dependent protein kinase II triggers atrial fibrillation. Circulation 2013; 128: 1748–1757.
142. Luo M, et al. Diabetes increases mortality after myocardial infarction by oxidizing CaMKII. J Clin Invest 2013; 123: 1262–1274.
143. He BJ, et al. Oxidation of CaMKII determines the cardiotoxic effects of aldosterone. Nature Med 2011; 17: 1610–1618.
144. Zhang R, et al. Calmodulin kinase II inhibition protects against structural heart disease. Nature Med 2005; 11: 409–417.
145. Swaminathan PD, et al. Calmodulin-dependent protein kinase II: linking heart failure and arrhythmias. Circ Res 2012; 110: 1661–1677.
146. Cox AJ, et al. Polymorphisms in the Selenoprotein S gene and subclinical cardiovascular disease in the Diabetes Heart Study. Acta diabetologica 2013; 50: 391–399.
147. Alanne M, et al. Variation in the selenoprotein S gene locus is associated with coronary heart disease and ischaemic stroke in two independent Finnish cohorts. Human Gen 2007; 122: 355–365.
148. Klein I, Ojamaa K. Thyroid hormone and the cardiovascular system. N Engl J Med 2001; 344: 501–509.
149. Klein I, Ojamaa K. Thyroid hormone-targeting the heart. Endocrinology 2001; 142: 11–12.
150. Trivieri MG, et al. Cardiac-specific elevations in thyroid hormone enhance contractility and prevent pressure overload-induced cardiac dysfunction. Proc Natl Acad Sci USA 2006; 103: 6043–6048.